Tesamorelin's Amino Acid Sequence vs. Native GHRH(1-44)

Tesamorelin’s amino acid sequence matches native growth hormone-releasing hormone across all 44 residues of GHRH(1-44). The peptide backbone is not shortened, reordered, or substituted at any position. The one structural change is a small lipophilic group attached to the N-terminal tyrosine residue, added to slow enzymatic breakdown rather than to alter how the sequence is recognized by its receptor. Understanding that distinction clarifies what “GHRH analog” means on a listing and why tesamorelin is described differently from other synthetic GHRH fragments.

Native GHRH(1-44) as the reference sequence

Growth hormone-releasing hormone is produced in the hypothalamus as a 44-amino-acid peptide, commonly written as GHRH(1-44). Research into the hormone’s structure-activity relationship established that the N-terminal 29 residues, GHRH(1-29), carry the portion of the sequence needed to activate the GHRH receptor. The remaining residues, extending out to position 44, are part of the naturally secreted form and contribute to how the full-length peptide behaves once it is released, including its C-terminal amidation. When a listing or reference sheet cites “GHRH(1-44),” it is describing this full endogenous sequence, not a truncated laboratory fragment.

Where tesamorelin’s sequence lines up

Tesamorelin is built on that same 44-residue backbone. Position for position, the amino acid sequence corresponds to native GHRH(1-44), including the C-terminal amidation pattern associated with the naturally occurring peptide. This is a meaningful distinction from some other GHRH-derived research peptides, which shorten the chain to the 1-29 core or substitute individual residues to change stability. Tesamorelin does neither. The sequence itself is left intact, which is part of why documentation for tesamorelin often describes it as an “analog of GHRH(1-44)” rather than a fragment or a mutated variant.

The one modification: N-terminal acylation

The change that does exist sits entirely outside the amino acid chain. A trans-3-hexenoic acid group, a small lipophilic (fat-compatible) acyl chain, is attached to the N-terminal tyrosine residue. This addition does not replace or remove any amino acid; it is appended to the existing structure at the very start of the sequence.

The functional reason for this modification relates to enzymatic degradation. Native GHRH is a substrate for the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two residues from the N-terminus and inactivates the peptide quickly once it is in circulation. The acyl group on tesamorelin’s N-terminal tyrosine sits directly at that cleavage site, which is the mechanism proposed for why the modified peptide resists DPP-4 processing more effectively than the unmodified native sequence. In short, the sequence tells the receptor what to bind; the acyl group determines how long an intact peptide is available to do so.

Why modify stability instead of the sequence

Different GHRH-based research peptides take different approaches to the same underlying problem, which is that native GHRH degrades quickly. Some address it by substituting amino acids within the 1-29 core itself, changing specific residues to resist enzymatic cleavage or aggregation. Tesamorelin’s approach leaves the sequence untouched and instead adds an external chemical group. Researchers comparing analytical documentation across peptides, including HEEZ Research tesamorelin, are effectively comparing two different design philosophies for the same starting sequence: modify the chain, or modify what happens at one end of an otherwise unmodified chain.

Sequence comparison at a glance

Feature	Native GHRH(1-44)	Tesamorelin
Chain length	44 amino acids	44 amino acids
Core receptor-binding region	Residues 1-29	Residues 1-29 (unchanged)
Residues 30-44	Present, as secreted	Present, unchanged
C-terminal amidation	Present	Present
N-terminal residue	Tyrosine (free)	Tyrosine, acylated with trans-3-hexenoic acid
Primary vulnerability addressed	N/A	N-terminal DPP-4 cleavage site

What this means for reading a listing or COA

Because the acylation site is a single, defined addition rather than a scattered set of substitutions, it is a feature that analytical documentation can specifically confirm. A certificate of analysis that reports mass spectrometry data alongside standard purity figures gives a way to distinguish an intact, correctly modified peptide from a preparation where that N-terminal group is missing or degraded, since an unmodified peptide would show a different measured mass than the acylated form. Sequence identity alone, stated as “GHRH(1-44) analog” on a label, does not confirm that the modification is present and intact; the analytical data behind that label does.

This also explains why sourcing documentation for tesamorelin tends to emphasize mass-based confirmation rather than sequence confirmation alone. The amino acid sequence is, by design, identical to a naturally occurring reference standard, so sequence matching by itself cannot distinguish tesamorelin from unmodified GHRH(1-44) or verify that the acyl group survived synthesis and storage intact.

The broader GHRH-GH-IGF-1 signaling axis that this peptide interacts with continues to be an active subject of study, including work examining how chronic inflammation affects growth hormone and IGF-1 axis signaling and more recent research on nutrition’s relationship to GH/IGF-1 signaling. That ongoing research context is separate from the structural question of sequence identity, but it explains why the distinction between a modified and unmodified N-terminus is treated as analytically significant rather than a minor labeling detail.

Summary

Tesamorelin’s amino acid sequence is not a shortened or rewritten version of native GHRH(1-44); it is the same 44-residue chain, including the same core receptor-binding region and C-terminal amidation. The single point of difference is a lipophilic acyl group attached to the N-terminal tyrosine, positioned to interfere with the enzymatic cleavage that normally inactivates the native hormone quickly. Recognizing that the sequence is unchanged, and that the modification lives entirely at one end of the molecule, is what makes mass-based analytical confirmation, rather than sequence description alone, the meaningful way to verify a tesamorelin preparation against native GHRH(1-44).